Zusammenfassung
Bei allen Formen der renoparenchymatösen Hypertonie (s. Kapitel 13.1) ist eine Blutdrucksenkung auf Werte < 130/80 mmHg anzustreben, um einerseits die Progression der Niereninsuffizienz zu verzögern und andererseits eine Schädigung weiterer Endorgane zu vermeiden. Ist die tägliche Eiweißausscheidung > 1 g, so ist der Blutdruck möglichst auf 125/75 mmHg zu senken. Die zeitliche Verzögerung der Niereninsuffizienz durch eine Senkung des Blutdruckes konnte sowohl bei der diabetischen Nephropathie (s. Kapitel 31.5.1) als auch bei nichtdiabetisch bedingten Nierenerkrankungen (IgA-Glomerulonephritis, hypertensive Nephropathie) eindrücklich belegt werden.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Al-Sobhi S, Peschel R, Bartsch G, Gasser R, Finkenstedt G, Janetschek G (2000) Partial laparoscopic adrenalectomy for aldosterone-producing adenoma: short-and long-term results. J Endourol 14:497–499
Averbusch S, Streakley C, Young R, Gelmann E, Goldstein D, Stull R, Keiser H (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 109:267–273
Benoit G, Moukarzel M, Hiesse C, Verdelli G, Charpentier B, Fries D (1990) Transplant renal artery stenosis: experience and comparative results between surgery and angioplasty. Transplant Int 3:137–140
Blum U, Krumme B, Flügel P, Gabelmann A, Lehnert T, Buitrago-Tellez C, Schollmeyer P, Langer M (1997) Treatment of ostial renal-artery stenosis with vascular endoprotheses after unsuccessful balloon angioplasty. N Engl J Med 336:459–465
Bravo EL, Gifford RW (1984) Pheochromocytoma: diagnosis, localization, and management. N Engl J Med 311:1298–1303
Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V. Deutsche Hypertonie Gesellschaft (1997) Renovaskuläre Hypertonie, Merkblatt, 2. Auflage. Heidelberg
Ganguly A (1990) Glucocorticoid-suppressible hyperaldosteronism: an update. Am J Med 88:321–324
Ghose RP, Hall PM, Bravo EL (1999) Medical management of aldosterone-producing adenomas. Ann Intern Med 131:105–108
Gifford RW, Manger WM, Bravo EL (1994) Pheochromocytoma. Endocrinol Metab Clin N Am 23:387–404
Groth H, Vetter W, Stimpel M, Greminger P, Tenschert W, Klaiber E, Vetter H (1985) Adrenalectomy in primary aldosteronism: a long-term follow-up study. Cardiology 72(suppl l):107–116
Guo J, Gong L, Chen S, Luo B, Xu M (1989) Malignant pheochromocytoma: diagnosis and treatment in fifteen cases. J Hypertens 7:261–266
Harden PN, MacLeod MJ, Rodger RSC, Baxter GM, Connell JMC, Dominiczak AF, Junor BJR, Briggs JD, Moss JG (1997) Effect of renal-artery stenting on progression of renovascular renal failure. Lancet 349:1133–1136
Ibrahim HAA, Vora JP (1999) Hypertension in diabetes: a good opportunity to practise evidence-based medicine? A commentary on the UKPDS. J Hypertension 13:221–223
Irvin GL, Carneiro DM (2000) Management changes in primary hyperparathyroidism. JAMA 284:936–938
Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C, Guyot M, Lahneche B, Marchandise X, Schlumberger M, Charbonnel B, Chatal JF (1991) Use of m-131-iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72:455–461
Lafferty FW, Hubay CA (1989) Primary hyperparathyroidism. A review of the long-term surgical and nonsurgical morbidities as a basis for a rational approach to treatment. Arch Intern Med 149:789–796
Manger WM, Gifford RW (1993) Pheochromocytoma: current diagnosis and management. Clev Clin J Med 60:365–378
Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Maschio G (2000) The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int 57(suppl 75): S44–S48
Olyaei AJ, de Mattos AM, Bennett WM (1999) A practical guide to the management of hypertension in renal transplant recipients. Drugs 58:1011–1027
Orth DN (1995) Cushing’s syndrome. N Engl J Med 791–803
Pelegri A, Romero R, Reguant M, Aisa L (1989) Non-resectable phaeochromocytoma: long-term follow-up. J Hum Hypertension 3:145–147
Plouin PF, Chatelier G, Fofol I, Corvol P (1997) Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29:1133–1139
Plouin PF, Chatelier G, Darné B, Raynaud A for the Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group (1998) Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis. A randomized trial. Hypertension 31:823–829
Pommier RF, Brennan MF (1992) An 11-year experience with adrenocortical carcinoma. Surgery 112:963–971
Ramsay LE, Waller PC (1990) Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. Br Med J 300:569–572
Ritz E, Mann JFE (2000) Renal angioplasty for lowering blood pressure. N Engl J Med 342:1042–1043
Rosenthal T (1993) Drug therapy of renovascular hypertension. Drugs 45:895–909
Russo D, Andreucci VE, Iaccarino V, Niola R, Dal Canton A, Conte G (1988) Percutaneous renal embolisation in renovascular hypertension. Br Med J 296:1160–1161
Semple PF, Dominiczak AF (1994) Detection and treatment of renovascular disease: 40 years on. J Hypertens 12:729–734
Shimon I, Melmed S (1998) Management of pituitary tumors. Ann Intern Med 129:472–483
Stimpel M, Wambach G (1987) Therapie des Phäochromozytoms. Dtsch med Wschr 112:1426–1427
Stimpel M (1992) Therapie des primären Aldosteronismus. Dtsch med Wschr 117:947–949
Swearingen B, Biller BMK, Barker FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT (1999) Long-term mortality after transsphenoidal surgery for Cushing’s disease. Ann Intern Med 130:821–824
Tanaka M, Tokuda N, Koga H, Kimoto Y, Naito S (2000) Laparoscopic adrenalectomy for pheochromocytoma: comparison with open adrenalectomy and comparison of laparoscopic surgery for pheochromocytoma versus other adrenal tumors. J Endourol 14:427–431
Troncone L, Rufini V (1999) Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 43:344–355
Tyagi S, Singh B, Kaul UA, Sethi KK, Arora R, Khalilullah (1993) Balloon angioplasty for renovascular hypertension in Takayasu’s arteritis. Am Heart J 125:1386–1393
Van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FHM, Deinum J, Postma CT, Dees A, Woittiez AJJ, Bartelink AKM, Man in’t Veld A, Schalekamp MADH for the Dutch Renal Artery Stenosis Intervention Cooperative Study Group (2000) The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 342:1007–1014
Vetter W, Robertson JIS, Grim CE, Lüscher TF, Malborough J (1986) (eds) Renovascular hypertension. In memoriam Andreas Grüntzig. Cardiology 44(suppl 1):1–114
Yamakita N, Chiou S, Gomez-Sanchez CE (1991) Inhibition of aldosterone biosynthesis by 18-ethynyl-deoxycorticosterone. Endocrinology 129:2361–2366
Young WF Jr, Hogan MJ, Klee GG, Grant CS, van Heerden JA (1990) Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 65:96–110
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2001 Steinkopff Verlag Darmstadt
About this chapter
Cite this chapter
Stimpel, M. (2001). Spezifische Therapie sekundärer Hypertonieformen. In: Arterielle Hypertonie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57617-1_34
Download citation
DOI: https://doi.org/10.1007/978-3-642-57617-1_34
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-642-63309-6
Online ISBN: 978-3-642-57617-1
eBook Packages: Springer Book Archive